SOLICITATION NOTICE
Q -- Affymetrix Whole Axiom Exome Plate Arrays
- Notice Date
- 6/29/2012
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HG)-2012-205-DLM
- Archive Date
- 7/18/2012
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Affymetrix, 3420 Central Expressway, Santa Clara, California 95051 to procure the following: 1. Plate, Axiom Exome 1 96-Array, Item Number: 550396, Quantity: Twenty-Four (35) Box. 2. VAT/Duty Shipping Charges, Item Number: 000126, Quantity: One-Thousand Fifty-Six (1056) Each. 3. Services Charges, Item Number: 000126, Quantity: One-Thousand Fifty-Six (1056) Each. The sole source determination is based on the fact that National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency conducting and supporting medical discoveries that improve people's health and save lives. The National Human Genome Research Institute (NHGRI), The Center for Research on Genetics and Global Heath (CRGGH) lab has ongoing large-scale genetic epidemiology studies of metabolic disorders including obesity, type 2 diabetes (T2D), hypertension, dyslipidemia in African Americans, Africans and Chinese. Over 8,000 DNA and other biological specimen have been collected, processed and stored on study participants. The goal of these projects is to identify the genetic and non-genetic contributors to several metabolic disorders with the ultimate goal of informing the health disparity observed in African Americans compared to their European counterparts. By developing genetic epidemiology models to investigate the complex interaction between genetic and lifestyle factors, the CRGGH lab hopes to shed light on the patho-biology of metabolic diseases in different human populations especially African Americans. In this project, CRGGH is proposing to use the whole exome array which contains over 300,000 coding SNPs including non-synonymous and synonymous SNPs as well as variants in splice and stop codons. It also has about 30,000 single-base and complex indels from the draft Phase 1 1000 Genomes Project exome calls. All markers have low linkage disequilibrium (LD) and span both autosomes and chromosome X. The GWAS tags includes over 5,000 SNPs reported in the NHGRI Catalog of Published Associations (August 2011) and additional unpublished hits from scientific collaborations. Importantly, this chip can be customized to include about 100,000 SNPs from candidate genes that we are interested in directly interrogating in the lab. CRGGH projects in the USA, Africa and China were designed to identify susceptibility genes to several metabolic diseases in African and non-African ancestral populations with the ultimate goal of providing insights into the increased susceptibility seen in African Americans. Collectively, these large-scale genetic epidemiology projects in the US, Africa (Nigeria, Ghana and Kenya) and China have enrolled over 8,000 participants with carefully implemented informed consent procedures to facilitate the study of the genetic and non-genetic basis of metabolic diseases. Due to differences in socioeconomic factors including lifestyle characteristics (e.g., reduced calorie intake, higher level of physical activities and lower BMI), the incidence of T2D in the recruited African and Asian American populations are lower than in African Americans. The Affymetrix Axiom Genotyping Exome Array, Axiom 2.0 Reagent Kit and the Affymetrix GeneTitan Instrument platform with Genotyping Console software is a unique and completely integrated microarray analysis solution for genomics research available solely from Affymetrix. The Axiom Exome Array contains approximately 319,000 unique markers and optionally 100,000 custom markers, providing the most comprehensive panel to screen for putative functional variants in the protein coding regions of the human genome. Purpose and Objectives for the Procurement : SPECIFIC AIMS : 1. Use the whole exome array chip developed and manufactured by the contractor to genotype 3,360 DNA samples. 2. Conduct whole-exome association study on several traits including obesity, T2D and related complications, blood pressure parameters (hypertension, systolic and diastolic BP), lipid parameters (HDL, LDL, triglycerides and total cholesterol) and kidney function parameters (eGFR, creatinine, and Albumin). 3. Perform a replication study of whole-exome association study findings in independent samples of African Americans, Africans, Chinese and European ancestry populations. • Replication studies allow for verification of novel findings and/or refining the position of previously discovered genetic variants associated with the metabolic traits of interest. Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology, the Business Size Standard is 500 Employees. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-58 (May 18, 2012). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by July 3, 2012, 7:30 a.m. Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquiries to this announcement, referencing synopsis number NHLBI-CSB-(HG)-2012-205-DLM, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. Note: In order to receive an award from NHLBI, contractors must have a valid registration in the Central Contractor Registration (CCR) www.ccr.gov, and ORCA https://orca.bpn.gov/login.aspx.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HG)-2012-205-DLM/listing.html)
- Place of Performance
- Address: Will be used at NHGRI Projects at Children's Hospital in Philadelphia, Philadelphia, Pennsylvania, United States
- Record
- SN02790913-W 20120701/120629235316-88a731c04720196981eba8fe251b31e9 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |